RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies

J Wang,Y. Liu,Q Zhang,Jifeng Feng,Juemin Fang,Xuelian Chen,Yiqun Han,Q Li,P Zhang,Yuan P,Yuejun Luo,Y Fan,Runlan Cai,Shiliang Chen,Y. X. Li,B H Xu

RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies

2021

J Wang
Y. Liu
Q Zhang
Jifeng Feng
Juemin Fang
Xuelian Chen
Yiqun Han
Q Li
P Zhang
Yuan P
Yuejun Luo
Y Fan
Runlan Cai
Shiliang Chen
Y. X. Li
B H Xu

1022Background: Currently, there are no standard ≥3 line regimens recommended for HER2-positive (IHC 3+, or IHC 2+/FISH+) advanced or metastatic breast cancer, and no recommended HER2-targeting tre...

Keywords:

Medicine
Immunohistochemistry
Internal medicine
pooled analysis
in patient
Oncology
Antibody-drug conjugate
Metastatic breast cancer
2019 20 coronavirus outbreak
Fish <Actinopterygii>
severe acute respiratory syndrome coronavirus 2

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations